SEC Form 4 · accession 0001209191-17-038262
Epizyme, Inc. · EPZM
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Robert A Copeland
Officer — President of Research and CSO
Period of report
Jun 6, 2017
Accepted (ET)
Jun 7, 2017 · 1:48 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001571498
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Commons Stock, par value $0.0001 | Jun 6, 2017 | M | 2,500 | $3.54 | A | 34,038 | D | |
| Commons Stock, par value $0.0001 | Jun 6, 2017 | S | 2,500 | $13.45 | D | 31,538 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.54 | Jun 6, 2017 | M | 2,500 | D | — | Jan 24, 2023 | Common Stock | 2,500 | 36,050 | D |
Explanation of responses
- F1The exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- F2This option is fully vested.